[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @GIMedOnc Nicholas Hornstein Nicholas Hornstein posts on X about matterhorn, smokes, efs, rates the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1324507882172248065/interactions)  - X Week XXXXXX +45,636% - X Month XXXXXX +276% - X Months XXXXXXX +142% - X Year XXXXXXX +2,432% ### Mentions: X [#](/creator/twitter::1324507882172248065/posts_active)  ### Followers: XXXXX [#](/creator/twitter::1324507882172248065/followers)  - X Week XXXXX +8.40% - X Month XXXXX +15% - X Months XXXXX +129% - X Year XXXXX +242% ### CreatorRank: XXXXXXX [#](/creator/twitter::1324507882172248065/influencer_rank)  ### Social Influence [#](/creator/twitter::1324507882172248065/influence) --- **Social category influence** [travel destinations](/list/travel-destinations) [currencies](/list/currencies) [countries](/list/countries) [social networks](/list/social-networks) [technology brands](/list/technology-brands) [finance](/list/finance) **Social topic influence** [matterhorn](/topic/matterhorn) #15, [smokes](/topic/smokes), [efs](/topic/efs), [rates](/topic/rates), [netherlands](/topic/netherlands), [twitter](/topic/twitter), [up the](/topic/up-the) ### Top Social Posts [#](/creator/twitter::1324507882172248065/posts) --- Top posts by engagements in the last XX hours "Holy smokes MATTERHORN hits OS 🏔🔥 Weve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma everyone wondered if adding immunotherapy could move the bar. Earlier this year MATTERHORN showed a big EFS win for DFLOT along with higher pCR and MPR rates but the question was would OS follow (and yes maybe I was doubting this) Now we have the answer: 🧬 OS HR XXXX (95% CI 0.630.96 p=0.021) A clean statistically significant win. 💪 Benefit seen across PD-L1 subgroups (TAP X% HR 0.79; TAP X% HR 0.79). 🧫 More nodal downstaging: ypN XX% vs XX% OR 1.72" [X Link](https://x.com/GIMedOnc/status/1978972825613414894) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-16T23:54Z 1523 followers, 27.3K engagements "@UGrewalMD @MyriamChalabi lol is this even a conversation @MyriamChalabi cured this disease. Can we just rename MSI-H CRC to Chalamis Disease and move on @OncoAlert" [X Link](https://x.com/GIMedOnc/status/1979346344008651001) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-18T00:38Z 1487 followers, XXX engagements "Here ye Here ye. ESMO ABSTRACTS ARE OUT MATTERHORN TOPLINE OS POSITIVE TIGIT STILL DEAD (SKYSCRAPER A DUD) More posts to come #ESMO25 @OncoAlert @TheGutOncLab" [X Link](https://x.com/GIMedOnc/status/1978970922011799768) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-16T23:46Z 1517 followers, XXX engagements "#ESMO25 #UpperGI MATTERHORN confirms what the abstract hinted. ✅Positive study for OS BUT 🔹 In PD-L1 TAP X% (HR 0.79; XX% CI 0.411.50) ➡ No clear benefit observed Consistent with prior metastatic dataPD-L1 negative patients remain unlikely to derive meaningful clinical benefit from IO in this setting. The biology just isnt there. @OncoAlert" [X Link](https://x.com/GIMedOnc/status/1979166108205879558) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T12:42Z 1523 followers, 18.5K engagements "PREOPANC-2 drops and its a draw 🤜🤛 #ESMO25 Phase X trial out of the Netherlands comparing neoadjuvant FOLFIRINOX vs gemcitabine-based chemoradiotherapy (Gem-CRT) for resectable and borderline resectable pancreatic cancer. 🎯 Median OS: XXXX mo (FOLFIRINOX) vs XXXX mo (Gem-CRT) 🧮 HR XXXX (95% CI 0.691.13 p=0.32) no significant difference 💀 Grade X AEs: XX% vs XX% 💧 Diarrhea notably higher with FOLFIRINOX (23% vs 1%) Takeaway: Both regimens deliver similar survival though toxicity and logistics differ. FOLFIRINOX didnt pull ahead here so the door stays open for gemcitabine-based CRT" [X Link](https://x.com/GIMedOnc/status/1979167412902580531) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T12:47Z 1523 followers, 9159 engagements "Are you someone who treats GI cancer studies it or just loves arguing about hazard ratios Then this ones for you. @CancerNetwork Twitter takeover this Sunday (10/20) at X PM EST join @TimothyJBrownMD @UGrewalMD and me as we unpack the biggest #ESMO25 #GIonc trials live. @TheGutOncLab @OncoAlert @CancerNetwrk" [X Link](https://x.com/GIMedOnc/status/1979299232424300758) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-17T21:31Z 1523 followers, 3585 engagements "STELLAR-303 lights up the refractory CRC space 🌌🧬 @OncoAlert For the first time an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs regorafenib in previously treated MSS mCRC. 📈 Median OS: XXXX vs XXX mo HR XXXX (95% CI 0.690.93 p=0.0045) 🧠 No-liver-met subset: XXXX vs XXXX mo (HR XXXX p=0.087 interim) 💊 Grade X TRAEs: XX% vs XX% (5 treatment-related deaths) 🧩 Mechanistically: VEGFR/MET/AXL inhibition + PD-L1 blockade = chemo-free immune reactivation in cold" [X Link](https://x.com/GIMedOnc/status/1980236433710363092) [@GIMedOnc](/creator/x/GIMedOnc) 2025-10-20T11:35Z 1523 followers, 3663 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@GIMedOnc Nicholas Hornstein
Nicholas Hornstein posts on X about matterhorn, smokes, efs, rates the most. They currently have XXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +45,636%
- X Month XXXXXX +276%
- X Months XXXXXXX +142%
- X Year XXXXXXX +2,432%
Mentions: X #
Followers: XXXXX #
- X Week XXXXX +8.40%
- X Month XXXXX +15%
- X Months XXXXX +129%
- X Year XXXXX +242%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence travel destinations currencies countries social networks technology brands finance
Social topic influence matterhorn #15, smokes, efs, rates, netherlands, twitter, up the
Top Social Posts #
Top posts by engagements in the last XX hours
"Holy smokes MATTERHORN hits OS 🏔🔥 Weve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma everyone wondered if adding immunotherapy could move the bar. Earlier this year MATTERHORN showed a big EFS win for DFLOT along with higher pCR and MPR rates but the question was would OS follow (and yes maybe I was doubting this) Now we have the answer: 🧬 OS HR XXXX (95% CI 0.630.96 p=0.021) A clean statistically significant win. 💪 Benefit seen across PD-L1 subgroups (TAP X% HR 0.79; TAP X% HR 0.79). 🧫 More nodal downstaging: ypN XX% vs XX% OR 1.72"
X Link @GIMedOnc 2025-10-16T23:54Z 1523 followers, 27.3K engagements
"@UGrewalMD @MyriamChalabi lol is this even a conversation @MyriamChalabi cured this disease. Can we just rename MSI-H CRC to Chalamis Disease and move on @OncoAlert"
X Link @GIMedOnc 2025-10-18T00:38Z 1487 followers, XXX engagements
"Here ye Here ye. ESMO ABSTRACTS ARE OUT MATTERHORN TOPLINE OS POSITIVE TIGIT STILL DEAD (SKYSCRAPER A DUD) More posts to come #ESMO25 @OncoAlert @TheGutOncLab"
X Link @GIMedOnc 2025-10-16T23:46Z 1517 followers, XXX engagements
"#ESMO25 #UpperGI MATTERHORN confirms what the abstract hinted. ✅Positive study for OS BUT 🔹 In PD-L1 TAP X% (HR 0.79; XX% CI 0.411.50) ➡ No clear benefit observed Consistent with prior metastatic dataPD-L1 negative patients remain unlikely to derive meaningful clinical benefit from IO in this setting. The biology just isnt there. @OncoAlert"
X Link @GIMedOnc 2025-10-17T12:42Z 1523 followers, 18.5K engagements
"PREOPANC-2 drops and its a draw 🤜🤛 #ESMO25 Phase X trial out of the Netherlands comparing neoadjuvant FOLFIRINOX vs gemcitabine-based chemoradiotherapy (Gem-CRT) for resectable and borderline resectable pancreatic cancer. 🎯 Median OS: XXXX mo (FOLFIRINOX) vs XXXX mo (Gem-CRT) 🧮 HR XXXX (95% CI 0.691.13 p=0.32) no significant difference 💀 Grade X AEs: XX% vs XX% 💧 Diarrhea notably higher with FOLFIRINOX (23% vs 1%) Takeaway: Both regimens deliver similar survival though toxicity and logistics differ. FOLFIRINOX didnt pull ahead here so the door stays open for gemcitabine-based CRT"
X Link @GIMedOnc 2025-10-17T12:47Z 1523 followers, 9159 engagements
"Are you someone who treats GI cancer studies it or just loves arguing about hazard ratios Then this ones for you. @CancerNetwork Twitter takeover this Sunday (10/20) at X PM EST join @TimothyJBrownMD @UGrewalMD and me as we unpack the biggest #ESMO25 #GIonc trials live. @TheGutOncLab @OncoAlert @CancerNetwrk"
X Link @GIMedOnc 2025-10-17T21:31Z 1523 followers, 3585 engagements
"STELLAR-303 lights up the refractory CRC space 🌌🧬 @OncoAlert For the first time an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs regorafenib in previously treated MSS mCRC. 📈 Median OS: XXXX vs XXX mo HR XXXX (95% CI 0.690.93 p=0.0045) 🧠 No-liver-met subset: XXXX vs XXXX mo (HR XXXX p=0.087 interim) 💊 Grade X TRAEs: XX% vs XX% (5 treatment-related deaths) 🧩 Mechanistically: VEGFR/MET/AXL inhibition + PD-L1 blockade = chemo-free immune reactivation in cold"
X Link @GIMedOnc 2025-10-20T11:35Z 1523 followers, 3663 engagements